TriSalus - התחייבויות לטווח ארוך של החברה TLSI

The TriSalus Life Sciences (TLSI) share price visualized below on the GURU.Markets platform reflects the dynamics of a company developing methods to combat stomach and liver cancer through partnerships with medical centers to create synergy between immunotherapy and drug delivery systems. Long-term debt stands at 0.04. The business scales through the sale of high-margin consumables, while current growth is driven by the supply of specialized infusion devices for precise tumor targeting.

Long-term debt reflects the total obligations with a maturity exceeding one year, determining the issuer's financial stability and capital structure. Investors analyze borrowing trends to identify risks of excessive leverage or growth potential. Assessing the issuer's long-term liabilities allows for a comparison between debt growth rates and the scale of the business. The stability of this metric confirms the reliability of TriSalus Life Sciences (TLSI) production facilities in Colorado and strict quality control of materials.